Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | PAICS | P22234 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522038 | 0.90 | LMNA (0.42) | HRH4HRH3PAICSNOS3NOS1 | |
| SCHEMBL18410254 | 0.87 | HRH3 (0.41) | HRH4HRH3LMNASIGMAR1MAPT | |
| SCHEMBL12802002 | 0.87 | HRH3 (0.38) | HRH4HRH3LMNASIGMAR1MAPT | |
| SCHEMBL1665137 | 0.85 | HRH3 (0.43) | HRH4HRH3LMNASIGMAR1MAPT | |
| SCHEMBL1662821 | 0.83 | MAPT (0.45) | HRH4HRH3LMNASIGMAR1MAPT | |
| SCHEMBL19287360 | 0.83 | CXCR4 (0.42) | HRH3PAICSLMNASIGMAR1MAPT | |
| SCHEMBL17247324 | 0.82 | HRH4 (0.47) | HRH4HRH3PAICSNOS3NOS1 | |
| SCHEMBL14699099 | 0.82 | HRH3 (0.45) | HRH4HRH3SIGMAR1ALDH1A1 | |
| SCHEMBL17076772 | 0.79 | MAPT (0.41) | PAICSLMNASIGMAR1MAPTKDM1A | |
| SCHEMBL21673614 | 0.78 | HRH3 (0.41) | HRH4HRH3PAICSLMNACSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2947084-B1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-9745320-B2 | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9745320-B2 | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150336982-A1 | Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof | SHANGHAI CHEMEXPLORER CO., LTD. (CN) | 2015-11-26 | — | — | US | disclosed |
| US-20150336982-A1 | Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof | SHANGHAI CHEMEXPLORER CO., LTD. (CN) | 2015-11-26 | — | — | US | disclosed |
| EP-2947084-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Chemexplorer Co., Ltd. (CN) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014111037-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海昀怡健康管理咨询有限公司 (CN) | 2014-07-24 | — | — | WO | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336982-A1 | Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof | JAK1, JAK2, JAK3 | HRH4 1912/4885HRH3 3547/4885PAICS 921/4885 |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | HRH4 69/4885HRH3 257/4885PAICS 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.